Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer

Published:2017-01-20 Issue:1 Volume:12 Page:e0170536
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Dalm Simone U.,Schrijver Willemijne A. M. E.,Sieuwerts Anieta M.,Look Maxime P.,Ziel - van der Made Angelique C. J.,de Weerd Vanja,Martens John W.,van Diest Paul J.,de Jong Marion,van Deurzen Carolien H. M.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference24 articles.

1. IACR. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012: International Agency for Research on Cancer (http://globocan.iarc.fr/Default.aspx, 29-04-2015); [29-04-2015]. http://globocan.iarc.fr/Default.aspx.

2. Biological subtypes of breast cancer: Prognostic and therapeutic implications;O Yersal;World J Clin Oncol,2014

3. Molecular portraits of human breast tumours;CM Perou;Nature,2000

4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005

5. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments;SM Bison;Clin Transl Imaging,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers;Cancer Imaging;2024-01-26

2. Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity;European Journal of Nuclear Medicine and Molecular Imaging;2022-08-11

3. GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals;Nuklearmedizin - NuclearMedicine;2022-06

4. Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy;Frontiers in Endocrinology;2021-09-01

5. Comparison of biological properties of [177Lu]Lu-ProBOMB1 and [177Lu]Lu-NeoBOMB1 for GRPR targeting;Journal of Labelled Compounds and Radiopharmaceuticals;2020-01-11